A pharmacy benefits manager ... administering prescription drug benefits on behalf of a Federal health care program ... shall ... reimburse an in-network pharmacy for the ingredient cost of a prescription drug in an amount equal to the sum of ... the national average drug acquisition cost ... and ... 2 percent ... or $25, whichever is less; [and] pay an in-network pharmacy a professional dispensing fee that is equal to the professional dispensing fee paid by the State in which the pharmacy is located under title XIX
Establish federal rules requiring pharmacy benefit managers administering federal health care prescription drug benefits to reimburse in-network pharmacies based on drug acquisition cost plus a limited add-on and a state Medicaid dispensing fee.
Occurrences
A pharmacy benefits manager administering prescription drug benefits on behalf of a Federal health care program shall reimburse an in-network pharmacy for the ingredient cost of a prescription drug based on national average drug acquisition cost or wholesale acquisition cost, plus 2 percent or $25, whichever is less, and pay a professional dispensing fee equal to the State Medicaid dispensing fee.
Evidence
Congress.gov lists Rep. Jake Auchincloss as sponsor of H.R.6609, introduced December 11, 2025. Its latest action was committee referral, and its status is Introduced, not enacted.
H.R.6609 would require Medicare Part D and Medicaid PBM reimbursement to use NADAC or WAC, add the lesser of 4 percent or $50, and pay the state Medicaid dispensing fee.
Congress.gov lists Rep. Jake Auchincloss as sponsor of H.R.6610, introduced December 11, 2025. Its latest action was referral to the House Oversight and Government Reform Committee, and its status is Introduced.
H.R.6610 would require PBMs administering FEHB prescription drug benefits to reimburse in-network pharmacies at NADAC or WAC plus the lesser of 4 percent or $50 and pay the state Medicaid professional dispensing fee.
Assessments
Auchincloss sponsored H.R.6609 and H.R.6610 in the 119th Congress, and the bills closely match the promised PBM reimbursement formula across Medicare Part D, Medicaid, and FEHB prescription drug benefits. However, the evidence shows both measures remained introduced/referred to committee and had not been enacted or implemented as federal rules. This is a serious legislative attempt but not fulfillment of the promised outcome.